Analyst consensus rating
BioAge Labs Analyst Rating: Buy
BIOA is rated Buy by 8 analysts with a $35.63 target. As of 2026-08-21.
Direct answer
BioAge Labs's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.63.
Forecast evidence checked August 21, 2026.
Get free BioAge Labs email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.61
- Average price target
- $35.63
- High price target
- $73.00
- Low price target
- $20.00
- Low target gap
- +108.1%
- Target upside
- +270.7%
- High target gap
- +659.6%
- Target range width
- 551.5%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioAge Labs?
BioAge Labs has a verified Buy consensus. The same dataset has an average price target of $35.63.
How far are BioAge Labs's low and high targets from the recorded price?
The low target implies +108.1%, while the high target implies +659.6%.
How many analysts are included in BioAge Labs's consensus?
The verified consensus includes 8 analysts.
How is BioAge Labs's target upside or downside calculated?
The average target of $35.63 is divided by the recorded price of $9.61, then one is subtracted to produce +270.7%. This does not guarantee a future return.
When was BioAge Labs's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.